Page 14 - Hematologic Malignancies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The study findings have implications for the identification of novel pathways with which to selectively target folate-metabolism blood cancers.

Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia (CLL) Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, discussed the updated findings from the phase 3 ALPINE trial of zanubrutinib vs ibrutinib in relapsed/refractory CLL (r/r CLL) at 39 months of follow-up.

Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients.Virtual KOL event will be held on Tuesday, December 12, 2023 at 7:00AM PST (4:00PM CET)MARSEILLE, France--(BUSINESS WIRE)--#immunotherapy--Innate Pharma S...

Zanubrutinib continued to demonstrate improved progression-free survival benefit over ibrutinib in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, according to extended follow-up data from the phase 3 ALPINE trial.

Obecabtagene autoleucel elicited durable responses in patients with relapsed or refractory B-cell acute lymphoblastic leukemia independent of leukemic burden at lymphodepletion, although better outcomes were observed in those with lower burden.